Medicina
Departamento
Hospital General de Elda
Elda, EspañaPublicacións en colaboración con investigadores/as de Hospital General de Elda (2)
2015
-
The concordance between patients' renal replacement therapy choice and definitive modality: Is it a utopia?
PLoS ONE, Vol. 10, Núm. 10
2004
-
Docetaxel plus epirubicin is a highly active, well-tolerated, first-line chemotherapy for metastatic breast cancer: Results of a large, multicentre phase II study
Cancer Chemotherapy and Pharmacology, Vol. 53, Núm. 1, pp. 75-81